FDG PET/CT predicts bone cancer patient survival

August 27, 2013

FDG PET/CT imaging prior to osteosarcoma surgery and chemotherapy may be able to provide a clearer picture of patient risk and prognosis, according to a study published Aug. 15 in the Journal of Nuclear Medicine .

The study assessed quantitative FDG PET/CT, and particularly volumetric and metabolic parameters, as a predictor for metastases-free survival in patients with osteosarcoma of the extremities. Researchers led by Byung Hyun Byun, MD, from the department of nuclear medicine, Korea Cancer Center Hospital at the Korea Institute of Radiological and Medical Sciences in Seoul, Korea, found that FDG PET/CT could in fact tip off how patients responded to therapy. The ability to better select patients based on pretreatment imaging and estimated survival could potentially effect patient management and clinical decision-making.